Is sandostatin for hormones?

What is Sandostatin used for in hormone regulation?

Sandostatin, also known as octreotide, is a synthetic version of a natural hormone called somatostatin. It's used to treat a variety of hormone-related disorders, including [1] tumors and overproduction of hormones like growth hormone, insulin, and vasoactive intestinal peptide (VIP).

Octreotide is prescribed to manage symptoms such as hormone-related diarrhea, flushing, and pain in patients with [2] carcinoid tumors. It's also used to treat acromegaly, a condition caused by an overproduction of growth hormone.

In the case of hormone-related disorders, Sandostatin works by binding to somatostatin receptors on the surface of hormone-producing cells. This binding action [3] reduces the release of excess hormones into the bloodstream, helping to alleviate symptoms associated with these conditions.

Comparing Sandostatin to other hormone treatments

Octreotide is often compared to other somatostatin analogs, such as lanreotide and pasireotide, which have similar mechanisms of action. These medications are used to treat a range of hormone-related disorders, including acromegaly, carcinoid syndrome, and neuroendocrine tumors.

Regulatory considerations and exclusivity

Sandostatin was first approved by the FDA in 1985 for the treatment of acromegaly. The patent for the drug has expired, and it is now available as a generic medication.

Patent information

According to DrugPatentWatch.com, the patent for Sandostatin expired in 2005. However, generic versions of the medication are still available, manufactured by multiple pharmaceutical companies.

References:

[1] "Octreotide for carcioid tumors." DrugPatentWatch.com. Accessed May 18, 2026.

[2] "Acromegaly treatment options." Mayo Clinic. Accessed May 18, 2026.

[3] "Octreotide (Sandostatin). " National Cancer Institute. Accessed May 18, 2026.

Sources:

1. DrugPatentWatch.com
2. Mayo Clinic
3. National Cancer Institute